Impact of chronic oral H2-antagonist therapy on left ventricular systolic function and exercise capacity

Daniel E. Hilleman, Syed M. Mohiuddin, M. A. Williams, J. M. Gannon, R. J. Mathias, L. J. Thalken

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

It has been suggested that H2-antagonists may adversely affect left ventricular systolic function. To assess the effects of cimetidine, famotidine, and ranitidine on exercise capacity and left ventricular systolic function, the authors conducted a randomized, double-blind, four-way crossover study in 15 healthy male volunteers with placebo control. Each subject underwent a maximal upright treadmill exercise test, aerobic metabolic assessment, and two-dimensional stress echocardiography on six separate occasions. The initial two treadmill exercise tests with aerobic metabolic assessment and stress echocardiography were performed to minimize the learning effect. In the final four evaluations, subjects were randomized to receive 7 days of oral treatment with cimetidine 400 mg twice daily, famotidine 40 mg daily, ranitidine 150 mg twice daily, and placebo. A comparison of exercise tests, aerobic metabolic assessment, and stress echocardiography results found no significant differences between any of the H2-antagonists and placebo. In addition, there were no significant differences in test results between cimetidine, famotidine, and ranitidine. Specifically, exercise treadmill time, maximal oxygen consumption, respiratory quotient, maximal exercise systolic and diastolic blood pressure, maximal exercise heart rate, left ventricular end-diastolic dimension, left ventricular end-systolic dimension, and ejection fraction were not different between treatments. The authors conclude that 7 days of oral treatment with cimetidine, famotidine, or ranitidine has no deleterious effect on exercisecapacity or left ventricular systolic function in healthy subjects.

Original languageEnglish
Pages (from-to)1033-1037
Number of pages5
JournalJournal of Clinical Pharmacology
Volume32
Issue number11
StatePublished - 1992

Fingerprint

Famotidine
Exercise Test
Left Ventricular Function
Ranitidine
Cimetidine
Stress Echocardiography
Exercise
Placebos
Healthy Volunteers
Blood Pressure
Therapeutics
Oxygen Consumption
Cross-Over Studies
Echocardiography
Heart Rate
Learning

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Impact of chronic oral H2-antagonist therapy on left ventricular systolic function and exercise capacity. / Hilleman, Daniel E.; Mohiuddin, Syed M.; Williams, M. A.; Gannon, J. M.; Mathias, R. J.; Thalken, L. J.

In: Journal of Clinical Pharmacology, Vol. 32, No. 11, 1992, p. 1033-1037.

Research output: Contribution to journalArticle

@article{1a35c5544c1a4ce59cfe08ad4509103a,
title = "Impact of chronic oral H2-antagonist therapy on left ventricular systolic function and exercise capacity",
abstract = "It has been suggested that H2-antagonists may adversely affect left ventricular systolic function. To assess the effects of cimetidine, famotidine, and ranitidine on exercise capacity and left ventricular systolic function, the authors conducted a randomized, double-blind, four-way crossover study in 15 healthy male volunteers with placebo control. Each subject underwent a maximal upright treadmill exercise test, aerobic metabolic assessment, and two-dimensional stress echocardiography on six separate occasions. The initial two treadmill exercise tests with aerobic metabolic assessment and stress echocardiography were performed to minimize the learning effect. In the final four evaluations, subjects were randomized to receive 7 days of oral treatment with cimetidine 400 mg twice daily, famotidine 40 mg daily, ranitidine 150 mg twice daily, and placebo. A comparison of exercise tests, aerobic metabolic assessment, and stress echocardiography results found no significant differences between any of the H2-antagonists and placebo. In addition, there were no significant differences in test results between cimetidine, famotidine, and ranitidine. Specifically, exercise treadmill time, maximal oxygen consumption, respiratory quotient, maximal exercise systolic and diastolic blood pressure, maximal exercise heart rate, left ventricular end-diastolic dimension, left ventricular end-systolic dimension, and ejection fraction were not different between treatments. The authors conclude that 7 days of oral treatment with cimetidine, famotidine, or ranitidine has no deleterious effect on exercisecapacity or left ventricular systolic function in healthy subjects.",
author = "Hilleman, {Daniel E.} and Mohiuddin, {Syed M.} and Williams, {M. A.} and Gannon, {J. M.} and Mathias, {R. J.} and Thalken, {L. J.}",
year = "1992",
language = "English",
volume = "32",
pages = "1033--1037",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "11",

}

TY - JOUR

T1 - Impact of chronic oral H2-antagonist therapy on left ventricular systolic function and exercise capacity

AU - Hilleman, Daniel E.

AU - Mohiuddin, Syed M.

AU - Williams, M. A.

AU - Gannon, J. M.

AU - Mathias, R. J.

AU - Thalken, L. J.

PY - 1992

Y1 - 1992

N2 - It has been suggested that H2-antagonists may adversely affect left ventricular systolic function. To assess the effects of cimetidine, famotidine, and ranitidine on exercise capacity and left ventricular systolic function, the authors conducted a randomized, double-blind, four-way crossover study in 15 healthy male volunteers with placebo control. Each subject underwent a maximal upright treadmill exercise test, aerobic metabolic assessment, and two-dimensional stress echocardiography on six separate occasions. The initial two treadmill exercise tests with aerobic metabolic assessment and stress echocardiography were performed to minimize the learning effect. In the final four evaluations, subjects were randomized to receive 7 days of oral treatment with cimetidine 400 mg twice daily, famotidine 40 mg daily, ranitidine 150 mg twice daily, and placebo. A comparison of exercise tests, aerobic metabolic assessment, and stress echocardiography results found no significant differences between any of the H2-antagonists and placebo. In addition, there were no significant differences in test results between cimetidine, famotidine, and ranitidine. Specifically, exercise treadmill time, maximal oxygen consumption, respiratory quotient, maximal exercise systolic and diastolic blood pressure, maximal exercise heart rate, left ventricular end-diastolic dimension, left ventricular end-systolic dimension, and ejection fraction were not different between treatments. The authors conclude that 7 days of oral treatment with cimetidine, famotidine, or ranitidine has no deleterious effect on exercisecapacity or left ventricular systolic function in healthy subjects.

AB - It has been suggested that H2-antagonists may adversely affect left ventricular systolic function. To assess the effects of cimetidine, famotidine, and ranitidine on exercise capacity and left ventricular systolic function, the authors conducted a randomized, double-blind, four-way crossover study in 15 healthy male volunteers with placebo control. Each subject underwent a maximal upright treadmill exercise test, aerobic metabolic assessment, and two-dimensional stress echocardiography on six separate occasions. The initial two treadmill exercise tests with aerobic metabolic assessment and stress echocardiography were performed to minimize the learning effect. In the final four evaluations, subjects were randomized to receive 7 days of oral treatment with cimetidine 400 mg twice daily, famotidine 40 mg daily, ranitidine 150 mg twice daily, and placebo. A comparison of exercise tests, aerobic metabolic assessment, and stress echocardiography results found no significant differences between any of the H2-antagonists and placebo. In addition, there were no significant differences in test results between cimetidine, famotidine, and ranitidine. Specifically, exercise treadmill time, maximal oxygen consumption, respiratory quotient, maximal exercise systolic and diastolic blood pressure, maximal exercise heart rate, left ventricular end-diastolic dimension, left ventricular end-systolic dimension, and ejection fraction were not different between treatments. The authors conclude that 7 days of oral treatment with cimetidine, famotidine, or ranitidine has no deleterious effect on exercisecapacity or left ventricular systolic function in healthy subjects.

UR - http://www.scopus.com/inward/record.url?scp=0026446860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026446860&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 1033

EP - 1037

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 11

ER -